

# Unusual Presentation of Bullous Pemphigoid: A Clinical Challenge

Juliet Suen MS<sup>1</sup>, Morgan Parker BS<sup>1</sup>, Forrest Roberson MD<sup>2</sup>, Zachary E. Holcomb MD<sup>1,2</sup>, and Douglas J. Grider MD<sup>1,2,3,4</sup>

<sup>1</sup>Virginia Tech Carilion School of Medicine (VTC SOM) <sup>2</sup>Division of Dermatology, Department of Internal Medicine, VTC SOM, <sup>3</sup>Dominion Pathology Associates, <sup>4</sup>Department of Basic Science Education, VTC SOM

## Background

**Bullous Pemphigoid (BP)** is the most common autoimmune subepidermal blistering disease (~80% of cases) that typically affects older adults (65-75 years). This condition is often characterized by autoantibodies to hemidesmosomal proteins (BP180, BP230), complement activation, and dermal-epidermal separation.

- Classic presentations include tense bullae, urticarial plaques, and severe pruritus, with atypical variants presenting as pruritus without bullae or with mucosal involvement (10–20%).
- Diagnosis requires correlation of clinical, histologic, and immunofluorescence findings.

This case is notable because BP with a “linear full-house” DIF pattern (IgA, IgG, IgM, C3) is highly unusual.

## Case Presentation

### Initial Presentation

- 66-year-old man with history of rheumatoid arthritis, lymphoma (remission), and cutaneous SCC
- Presented with pruritic, eczematous plaques on thigh → diagnosed as nummular dermatitis, treated with clobetasol

### Clinical Course

- Six months later, developed painful, pruritic blisters at trauma sites
- Lesions followed relapsing-remitting course over 3 months
- No oral lesions on exam, but photos showed intermittent oral involvement triggered by coarse foods

### Biopsy Findings

- Subepidermal bullous dermatosis with early dermal scarring
- Subtle vacuolar changes at dermoepidermal junction
- No fungal organisms or excess dermal mucin

### Direct Immunofluorescence (DIF)

- Linear deposition of IgA, IgG, IgM, and C3 (“full-house” pattern)

### Serology & IIF

- BMZ IgG positive on monkey esophagus substrate
- BP180 elevated; BP230, Type VII collagen, and DSG1/3 negative
- IgG localized to epidermal side of salt-split skin; IgA absent

### Other Labs

- CBC, CMP, IgE, UA, hepatitis panel, QuantiFERON gold all unremarkable

### Final Diagnosis

- Bullous pemphigoid with rare “full-house” DIF pattern

## Clinical Images




Fig. 1 Clinical findings (A) Left flank (B) Periumbilical Abdomen (C) Left calf (D) Oral lesion

## Histologic Findings




Fig. 2 H&E (A) Left Calf Shave Biopsy (10x) (B) Left Flank Shave Biopsy (10x) (C) Periumbilical Bulla (4x) (D) Periumbilical Bulla (10X)




Fig. 3 Direct Immunofluorescence periumbilical skin: (A) IgG (B) IgM (C) IgA (D) C3

## Discussion

### Typical Presentation

- Bullous pemphigoid (BP) most often presents with tense bullae and intense generalized pruritus.
- Atypical cases may show only pruritus without bullae or oral lesions (10–20% of patients) .

### Pathogenesis

- Autoantibodies against hemidesmosomal proteins (BP180, BP230) activate complement and damage the dermoepidermal junction.

### Histology & DIF Patterns

- BP can mimic urticaria or epidermolysis bullosa acquisita (EBA).
- DIF usually shows linear C3 ± IgG at the basement membrane zone; IgA/IgM are less common.
- The “full-house” linear deposition of IgA, IgG, IgM, and C3 in this case is extremely rare.

### Confirming the Diagnosis

- Despite unusual DIF, salt-split skin IIF showed IgG on the epidermal side, and serology confirmed BP180 antibody positivity.
- Type VII collagen antibody was negative, ruling out EBA.
- Literature supports that IgA/IgM positivity, while rare, can occur in BP.

### Significance

- To our knowledge, this is the first reported case of BP with a linear full-house DIF pattern.
- Highlights the variability of BP immunopathology and the importance of correlating clinical, histologic, and serology data.

## References

- [1] Kridin K, Bergman R. Assessment of the Prevalence of Mucosal Involvement in Bullous Pemphigoid. *JAMA Dermatol.* 2019;155(2):166–171. doi:10.1001/jamadermatol.2018.5049
- [2] Mutasim DF, Adams BB. Immunofluorescence in dermatology. *Journal of the American Academy of Dermatology.* 2001;45(6):803-824. doi:10.1067/mjd.2001.117518
- [3] Arbache ST, Nogueira TG, Delgado L, Miyamoto D, Aoki V. Immunofluorescence testing in the diagnosis of autoimmune blistering diseases: overview of 10-year experience. *An Bras Dermatol.* 2014;89(6):885-889. doi:10.1590/abd1806-4841.20143221
- [4] Maurice PD, Allen BR, Marriott DW, Powell RJ, Reeves WG. Skin immunofluorescence in the diagnosis of primary bullous diseases—a review of 279 cases. *Clin Exp Dermatol.* 1986;11(4):352-364. doi:10.1111/j.1365-2230.1986.tb00475.x
- [5] Cozzani E, Drosera M, Parodi A, Carrozzo M, Gandolfo S, Rebora A. Frequency of IgA antibodies in pemphigus, bullous pemphigoid and mucous membrane pemphigoid. *Acta Derm Venereol.* 2004;84(5):381-384. doi:10.1080/00015550410031825
- [6] Boch K, Hammers CM, Goletz S, et al. Immunoglobulin M pemphigoid. *J Am Acad Dermatol.* 2021;85(6):1486-1492. doi:10.1016/j.jaad.2021.01.017

The authors have no significant relationships with, or financial interests in, any commercial companies pertaining to this poster.